[Federal Register Volume 62, Number 35 (Friday, February 21, 1997)]
[Notices]
[Page 8041]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-4347]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Importation of Controlled Substances; Notice of Application
Pursuant to Section 1008 of the Controlled Substances Import and
Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in Schedule I or II and prior to issuing a
regulation under Section 1002(a) authorizing the importation of such a
substance, provide manufacturers holding registrations for the bulk
manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with Section 1311.42 of Title 21, Code of
Federal Regulations (CFR), notice is hereby given that on December 3,
1996, Noramco of Delaware, Inc., Division of McNeilab, Inc., 500 Old
Swedes Landing Road, Wilmington, Delaware 19801, made application to
the Drug Enforcement Administration to be registered as an importer of
the basic classes of controlled substances listed below:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Opium, raw (9600).......................... II
Poppy Straw Concentrate (9670)............. II
------------------------------------------------------------------------
The firm plans to import the listed controlled substances to
produce codeine phosphate, codeine sulfate, morphine sulfate, oxycodone
and hydrocodone.
Any manufacture holding, or applying for, registration as a bulk
manufacturer of these basic classes of controlled substances may file
written comments on or objections to the application described above
and may, at the same time, file a written request for a hearing on such
application in accordance with 21 CFR 1301.54 in such form as
prescribed by 21 CFR 1316.47.
Any such comments, objections, or requests for a hearing may be
addressed to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, United States Department of
Justice, Washington, D.C. 20537, Attention: DEA Federal Register
Representative (CCR), and must be filed no later than March 24, 1997.
This procedure is to be conducted simultaneously with and
independent of the procedures described in 21 CFR 1311.42(b), (c), (d),
(e), and (f). As noted in a previous notice at 40 FR 43745-46
(September 23, 1975), all applicants for registration to import basic
classes of any controlled substances in Schedule I or II are and will
continue to be required to demonstrate to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration that the requirements for such registration pursuant to
21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1311.42(a), (b), (c),
(d), (e), and (f) are satisfied.
Dated: February 7, 1997.
Gene R. Haislip,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 97-4347 Filed 2-20-97; 8:45 am]
BILLING CODE 4410-09-M
